LEXINGTON, Mass.-– N-of-One, the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed.

Guardant360 is the first pan-cancer blood test that helps oncologists prescribe the right treatments at the right time based on the changing genomics of a patient’s cancer. The test uses trace fragments of tumor DNA that are shed into the bloodstream (“cell-free DNA”) for reconstructing and sequencing a patient’s cancer to detect emergent alterations that can help oncologists better match patients to potential therapeutic options.

N-of-One’s clinical interpretation provides relevant biological and clinical knowledge related to the mutation profile of the identified tumor DNA, and links this state-of-the-art knowledge to relevant therapeutic strategies, including clinical trials, to support oncologists in making molecularly-informed, personalized treatment decisions.

“Guardant360 is the first comprehensive, non-invasive tumor sequencing test providing real-time answers,” said Helmy Eltoukhy, Ph.D., Guardant Health’s co-founder and chief executive officer. “Knowledge of genomic alterations in combination with potential therapies can be most helpful to an oncologist and the treatment of their patients.”

“N-of-One provides diagnostic companies with best in class, state-of-the-art biological and clinical knowledge relevant to each test’s findings” said Chris Cournoyer, CEO of N-of-One. “Leveraging N-of-One clinical knowledge enables diagnostic companies to scale their test volumes in a cost effective manner.”

About N-of-One

N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options. N-of-One’s team of experts has interpreted more than 7,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.

About Guardant Health

Guardant Health is focused on developing breakthrough diagnostic technologies that can transform cancer from a silent killer into a manageable disease. Guardant was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology. For more information, please visitwww.guardanthealth.com or call 1-855-698-8887.